United Therapeutics Slips Soft Mist Inhaler Filing Into 2027 After FDA Meeting
The company is also "treading water" on a triple-combination drug, and its oral ralinepag supplier carries a compliance flag.
United Therapeutics, which develops drugs for pulmonary arterial hypertension, will now file its soft mist inhaler application in 2027 rather than at the end of this year, Executive Vice President of Strategic Development Pat Poisson said on the company's third-quarter earnings call Wednesday.
A pre-planned FDA meeting resets the clock
Poisson said the company met the FDA to discuss its filing strategy, a session that was pre-planned. Afterward, he said, "additional work is going to be needed to support the application."
The company is working with its development partner to finish that work and set an updated filing timeline. Asked by a JPMorgan analyst what was new, Poisson said it was "not necessarily anything new," just more data in some areas. "I don't think we're particularly worried about it," he said. "It's just we need time to do it."
Treading water on the triple combination
A Jefferies analyst asked about the triple-combination program, given that a bioequivalence study was not sufficient. Poisson said the FDA gave that feedback and the company is looking for an alternate path the agency would accept. "We're just treading water," he said, while it works on options to present.
Separately, Poisson said the API supplier for oral ralinepag has an OAI compliance status, which stems from an inspection earlier this year. The company is working with the supplier to fix it so the FDA's target decision date is not affected, with alternative plans moving in parallel. The supplier recently gave the FDA updated information on corrective actions, he said.
Record quarter, and a ralinepag royalty buyout
The delays came on a call where President Michael Benkowitz cited record third-quarter revenue of $833 million, including record Tyvaso revenue of $504 million. He said the company received more than 1,000 referrals for a UT product in October, the most ever in a single month.
Chief Financial Officer James Edgemond said the buyout of Pfizer's royalty on ralinepag reflects confidence in the drug's revenue opportunity. Oral ralinepag has an FDA decision date of June 24 next year, he said. Edgemond called the price the result of extensive negotiations and said the company would not discuss details.
Chief Executive Martine Rothblatt described 14 programs in development and a strategy of "approve, then improve." Benkowitz said nebulized Tyvaso in IPF and ralinepag in PAH could each become multi-billion dollar growth drivers once approved.
The next hard date is June 24, the FDA's decision date for oral ralinepag, which the supplier's compliance status could affect.
Sources
- United Therapeutics (UTHR) Q3 Earnings Miss Estimates — Yahoo Finance
- United Therapeutics (UTHR) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates — Yahoo Finance
- United Therapeutics buys out Pfizer royalties (PFE:NYSE) | Seeking Alpha — seekingalpha.com
- United Therapeutics Q3 2026 Earnings Preview (NASDAQ:UTHR) | Seeking Alpha — seekingalpha.com
- United Therapeutics Corporation Reports Third Quarter 2026 Financial Results — businesswire.com